Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib,Liver International

当前位置： X-MOL 学术 › Liver Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
Liver International ( IF 6.0 ) Pub Date : 2021-07-12 , DOI: 10.1111/liv.15014
Ilario Giovanni Rapposelli ₁ , Toshifumi Tada ₂ , Shigeo Shimose ₃ , Valentina Burgio ₄ , Takashi Kumada ₅ , Hideki Iwamoto ₃ , Atsushi Hiraoka ₆ , Takashi Niizeki ₃ , Masanori Atsukawa ₇ , Hironori Koga ₃ , Masashi Hirooka ₈ , Takuji Torimura ₃ , Massimo Iavarone ₉ , Raffaella Tortora ₁₀ , Claudia Campani ₁₁ , Sara Lonardi _{12,

13} , Emiliano Tamburini ₁₄ , Fabio Piscaglia ₁₅ , Gianluca Masi ₁₆ , Giuseppe Cabibbo ₁₇ , Francesco Giuseppe Foschi ₁₈ , Marianna Silletta ₁₉ , Kunihiko Tsuji ₂₀ , Toru Ishikawa ₂₁ , Koichi Takaguchi ₂₂ , Kazuya Kariyama ₂₃ , Ei Itobayashi ₂₄ , Kazuto Tajiri ₂₅ , Noritomo Shimada ₂₆ , Hiroshi Shibata ₂₇ , Hironori Ochi ₂₈ , Satoshi Yasuda ₂₉ , Hidenori Toyoda ₂₉ , Shinya Fukunishi ₃₀ , Hideko Ohama ₃₀ , Kazuhito Kawata ₃₁ , Joji Tani ₃₂ , Shinichiro Nakamura ₂ , Kazuhiro Nouso ₂₃ , Akemi Tsutsui ₂₂ , Takuya Nagano ₂₂ , Takaaki Tanaka ₆ , Norio Itokawa ₇ , Tomomi Okubo ₇ , Taeang Arai ₇ , Michitaka Imai ₂₁ , Kouji Joko ₂₈ , Yohei Koizumi ₈ , Yoichi Hiasa ₈ , Margherita Rimini ₃₃ , Francesca Ratti ₃₄ , Luca Aldrighetti ₃₄ , Stefano Cascinu _{4,

35} , Andrea Casadei-Gardini _{4,

35}

Affiliation

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST, Meldola, Italy.
Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy.
Faculty of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Liver Unit, Cardarelli Hospital, Naples, Italy.
Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Department of Medical Oncology, Card. G. Panico Hospital of Tricase, Tricase, Italy.
Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, Azienda Ospedaliero Universitaria di Bologna, Italy.
Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy.
Department of Internal Medicine, Faenza Hospital, AUSL Romagna, Faenza, Italy.
Medical Oncology Unit, University Campus Bio-Medico, Rome, Italy.
Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Department of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Hepato-biliary Center, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan.
Hepatology Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Department of Gastroenterology and Neurology, Kagawa University School of Medicine, Kagawa, Japan.
Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Hepatobiliary Surgery Division, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.

Lenvatinib is a standard of care option in first-line therapy of advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in patients with HCC treated with lenvatinib, a possible association between occurrence and grading of adverse events (AEs) and outcome.

中文翻译：